Rentschler–Coriolis Partnership Reflects Demand for Connected Biopharma Workflows

Contract development and manufacturing organization Rentschler Biopharma and contract research and development organization Coriolis Pharma have entered a strategic collaboration intended to streamline the path from early drug formulation to full-scale manufacturing. The partnership, announced on Dec. 2, 2025, reflects broader industry pressures, including increasingly complex biologic modalities, evolving regulatory expectations, and growing interest in tailored manufacturing strategies that reduce risk across development stages (1).

Both companies, which each have operations in Germany and the United States, plan to offer coordinated services beginning in December 2025. For drug developers, the collaboration signals a shift toward tighter integration between formulation science and process development, an area often challenged by fragmented workflows, extended tech transfers, and delays caused by misaligned analytical and manufacturing approaches (2,3).

“By bringing together our individual areas of excellence, bioprocess development and manufacturing on our side, and scientific and analytical expertise in formulation development at Coriolis, we look forward to addressing complex challenges across the biopharmaceutical value chain more efficiently and faster,” said Benedikt von Braunmühl, CEO, Rentschler Biopharma, in a company press release (1). “This collaboration perfectly exemplifies our vision of advancing medicine to save lives. Together.”

Why does combining formulation and manufacturing expertise matter?

Under the agreement, Coriolis Pharma will contribute in-silico and wet-laboratory-based formulation capabilities, along with analytical methods applied from research through compliance-driven manufacturing stages. These capabilities have become increasingly important as developers work with more diverse molecule formats, including multi-specific antibodies, next-generation proteins, and novel therapeutic designs that can be sensitive to process conditions (1,4).

For its part, Rentschler Biopharma will contribute its experience in bioprocess development and production for a range of biotherapeutics. The company’s background in supporting programs from early development through commercial supply allows it to handle scaling challenges that often arise when moving complex molecules toward the clinic, according to the company (1). By aligning project teams early, the collaboration aims to reduce uncertainties associated with tech transfer—an ongoing industry concern that can slow progress and increase regulatory risk (3).

“This collaboration is a testament to our Coriolis partnering strategy, which fosters synergistic relationships across the biopharma ecosystem,” said Silvia Steyrer-Gruber, CEO, Coriolis Pharma, in the release (1). “Together, we can provide clients with connected, science-driven solutions that help them move their projects forward towards success. Our teams look forward to working closely with Rentschler Biopharma on this collaboration.”

What industry needs will this collaboration address?

The collaboration responds to a market in which developers face mounting pressure to shorten development timelines while meeting heightened regulatory expectations for characterization, stability, and manufacturing robustness (5). Integrating formulation research with process design may help reduce the number of iterations needed to reach a commercially viable process, potentially lowering program risk (1).

For companies working across global hubs, Rentschler Biopharma and Coriolis Pharma’s combined presence in Europe and the US offers access to localized development resources while maintaining continuity in scientific oversight, which the partners expect may support small and mid-sized developers that often seek external partners to bridge technical gaps spanning formulation, analytics, and manufacturing (1).

By formally structuring a unified interface for clients, the two companies can better address bottlenecks that have traditionally separated early drug-product development from manufacturing readiness (1). The broader industry impact may come from demonstrating how coordinated scientific and operational planning can improve reliability and predictability for increasingly complex biologics (1,6).

References

1. Rentschler Biopharma. Rentschler Biopharma and Coriolis Pharma Announce Strategic Collaboration for Integrated Biopharma Solutions. Press Release. Dec. 2, 2025.
2. Ade, R. N.; Patil, R. V.; Khadatkar, S. N.; Marathe, S. J. An Overview on Technology Transfer. Int. J. TechnoChem Res. 2016, 2 (2), 164–177.
3. Kumar, S.; Luthra, S.; Haleem, A.; et al. Identification and Evaluation of Critical Factors to Technology Transfer Using AHP Approach. International Strategic Management Review 2015, 3 (1–2), 24–42. DOI: 10.1016/j.ism.2015.09.001
4. Amash, A.; Volkers, G.; Farber, P.; et al. Developability Considerations for Bispecific and Multispecific Antibodies. mAbs 2024, 16 (1), 2394229. DOI: 10.1080/19420862.2024.2394229
5. Rantanen, J.; Khinast, J. The Future of Pharmaceutical Manufacturing Sciences. J. Pharm. Sci. 2015, 104 (11), 3612–3638. DOI: 10.1002/jps.24594
6. FDA. Centers for Biologics Evaluation and Research (CBER) 2021–2025: Strategic Plan. FDA.gov (accessed Dec. 2, 2025).